title: Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database.
abstract: Economic evaluation of drugs is used in decision-making on medical care and public policy. Recently, real-world data (RWD) have been used in the analysis. In this study, we discuss the risk and benefits of using RWD for economic evaluation. We conducted a cost-outcome description with RWD from a nationwide registry providing information on hepatitis treatment in Japan and estimated the utility of the analysis. We evaluated the cost-outcome description of peginterferon plus ribavirin (PEG-IFN-α2b+RBV) treatment in hepatitis C virus (HCV)-infected patients. Simulations were based on a Markov model. The cohorts were set using data from the registry and we assumed a societal perspective for the calculation of costs. The dose and drug cost were chosen based on the Japanese Guidelines for the Management of Hepatitis C Virus Infection or package inserts. Model details and parameters were as described in previous studies. The simulations were performed for a period of 10 years with no discount rate. We estimated 2.5 million JPY per Quality Adjusted Life Year (QALY) in 48-week PEG-IFN-α2b+RBV treatment for a period of 10 years. The results of this study are in agreement with previous HCV treatment economic evaluation studies in Japan. We analyzed the statistics of the HCV-infected patients at each disease stage using the data in our registry and calculated the costs. The results of this study more closely reflect a real-world clinical situation compared to the widely used randomized clinical trial method, which estimates clinical trial results and scenarios.
authors.affiliation: Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka.
authors.forename: Maiko
authors.initials: M
authors.lastname: Akutagawa
authors.affiliation: Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka.|Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Kawasaki
authors.affiliation: Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Kawasaki
authors.affiliation: Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka.|Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Ide
authors.affiliation: Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamada
authors.affiliation: Laboratory Testing Department, National Center for Global Health and Medicine.
authors.forename: Naohiko
authors.initials: N
authors.lastname: Masaki
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D016527:Drug Costs; D017048:Health Care Costs; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; C000614170:Interferon-alpha2b; D012254:Ribavirin
keywords: economic evaluation; hepatitis c virus; peginterferon; real-world data; registry; ribavirin